A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals
[Pamplona, November 26 2019] 3P Biopharmaceuticals,
a leading Contract Development and Manufacturing Organization (CDMO)
specialized in process development and cGMP manufacturing of biologics,
has been chosen by In3Bio, a UK based Biotech company, to collaborate in
the development of a novel anti-tumour treatment.
More info >> |